Sorrento Therapeutics Reports Promising Phase 1b Results of COVI-MSC in COVID ICU Patients

On January 26, Sorrento Therapeutics, Inc.  (SRNE) announced preliminary results from a Phase 1b study of COVID-MSC for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). COVI-MSC is an infusion treatment of human allogeneic adipose-derived mesenchymal stem cells. The three patients in the study experienced no infusion-related adverse effects and were discharged from the hospital within 8 days of the initial IV infusion.

Jet Equities detected the event and alerted subscribers at 7:09 pm. The next trade took place at 7:10 pm for $11.32. The stock price followed a familiar pattern of rising quickly in the first four hours of regular market trading before pulling back a little in the afternoon. Sorrento’s stock price then moved higher again before the market close at $15.23. That makes an event-day gain of 35% for Sorrento investors.

 

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

Subscribe here if you would like to start receiving these signals in real-time and start trading!